8 Dividend Stocks You Can't Ignore in 2025
Welcome back to another insightful episode of Market Mondays! 💼 In this installment, Rashad Bilal and Ian Dunlap dive deep into eight dividend stocks that should be on your radar as we move through 2025. 🎯
Timestamps:
00:00 - Introduction
00:07 - Chevron: Worth the Investment?
01:04 - Verizon: A Reliable Choice?
01:43 - Pfizer: Potential for Growth?
02:30 - UPS: Long-Term Investment?
02:56 - T. Rowe Price: Underrated Gem?
03:35 - CVS: Past its Peak?
04:52 - Kraft Heinz: To Buy or Not to Buy?
05:51 - Sirius XM: Warren Buffett's Move?
Featured Stocks:
1. *Chevron (CVX)* 🌍💧
- Known for its strong long-term returns, Chevron has had a rocky year but is expected to bounce back. Rashad discusses the price points at which this stock becomes a worthy investment.
2. *Verizon (VZ)* 📶
- A utility-type stock that pays a solid dividend, Rashad and Ian talk about why this company is a buy below $34 and how it fits into a diversified portfolio.
3. *Pfizer (PFE)* 💊
- Despite some management issues and the loss of exclusive rights to key drugs, Pfizer still holds promise, especially if you can get it at the right price points: $24, $15.46, or $23.10.
4. *UPS (UPS)* 📦
- A great stock for long-term holds, UPS remains a stable investment option, although the sector's competitiveness needs consideration.
5. *T. Rowe Price (TROW)* 📈
- Known for its decent dividends and being a stalwart in the financial space, Rashad expresses his approval for this stock, especially if it dips to $100 or below.
6. *CVS (CVS)* 🏥
- Once a pandemic darling, CVS is now struggling. It's a potential buy only if it drops to $31. Rashad warns against chasing dividends in underperforming companies like this one.
7. *Kraft Heinz (KHC)* 🍔
- A controversial pick, mainly due to concerns about product quality. Rashad and Ian discuss why this may not be the best dividend stock for your portfolio.
8. *Sirius XM (SIRI)* 📻
- Mystery surrounds Warren Buffett's significant stake in this company. Rashad and Ian debate possible reasons behind this intriguing investment, while also questioning its growth potential.
Key Takeaways: